Ireland inching closer to accepting IMF/EU support and strong manufacturing and leading indicators data from the US brought back the bulls worldwide. Nordic markets were up nearly 1.5%. Nokia was down on debt rating cut from Fitch. Clavis Pharma raised 154 million NOK in a private placement of 4,400,000 new shares.
FLSmitdth, which supplies complete plants, equipment and services to cement and minerals industries globally, went up 11.7% after reporting an EBITDA of 707 million DKK in Q3. The company adjusted EBIT-margin prognosis upwards for both cement and minerals division from 9% to 10%. Order intake was up by 77% during the first three quarters of the year compared to 2009. The company now expects cement kiln capacity of 60 million tonnes worldwide excluding China as opposed to previous expectations of 50 million tons.
1.10.2010 blog item mentioned Bionor Pharma’s decision to seize the development of therapeutic HIV-vaccine candidate Vacc-4x. Today the company reversed decision based on new findings. The company said it was surprised to notice a statistically significant viral load reduction toward the end of the study period in the people who were dozed with the vaccine. In the beginning of November I reported about a ’dead cat bounce’ in Bionor as a result of rumours from Sweden concerning the vaccine. The market reaction today was something more than just that as the stock gained nearly 200%, half-way back compared to the levels before the initial cancellation announcement. The company also reversed the 84.7 million NOK write-down concerning Vacc-4x.
No comments:
Post a Comment